clinical trial · NCT04323098
Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
Hemophilia Avaloctocogene roxaparvovec
brief summary
This Phase III clinical study will evaluate the safety and effectiveness of valoctocogene roxaparvovec in combination with prophylactic corticosteroids in patients with severe hemophilia A.
started
Dec 8, 2020
primary completion
Jan 27, 2023
completion
May 8, 2025
last updated
Oct 8, 2025
official title
A Phase 3b, Single Arm, Open-Label Study to Evaluate the Efficacy and Safety of BMN 270, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII, With Prophylactic Corticosteroids in Hemophilia A Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol